# Standalone measles, mumps, and rubella vaccines

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/standalone-measles-mumps-and-rubella-vaccines
Canonical HTML page: https://getyourbrief.com/entity/standalone-measles-mumps-and-rubella-vaccines

## Recent coverage (3 stories, network-wide)

### MMR Unbundling Could Add Millions of Syringes to U.S. Supply Chain
2026-08-13 15:52:09 · Sector: supply · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Trump's order to split the MMR vaccine into individual shots threatens to reverse decades of pediatric vaccine bundling, forcing manufacturers and distributors to source millions more syringes, vials, and cold-chain shipments. Procurement teams and clinics face uncertain demand forecasts and rising consumables costs.
Full story: https://getsupplybrief.com/story/trump-vaccine-order-supply-chain-mmr-syringes

### Trump's 90-Day Vaccine Unbundling Plan Risks Lower Immunization Rates
2026-08-13 15:52:03 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Clinicians and public health officials warn the executive order to split the MMR vaccine and space out injections could reduce childhood immunization completion. Pediatric practices face more visits, more documentation, and higher costs with no clinical benefit identified.
Full story: https://gethealthbrief.com/story/trump-vaccine-unbundling-public-health-risk

### MMR Unbundling Would Cost Drugmakers Tens of Millions to Revive Old Shots
2026-08-13 15:51:55 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Biopharma executives face a potential forced revival of discontinued single-antigen measles, mumps, and rubella vaccines, requiring new manufacturing lines and regulatory work. Analysts estimate tens of millions in upfront costs and years of development before any unbundled schedule could be supplied.
Full story: https://getbiobrief.com/story/mmr-unbundling-biopharma-regulatory-cost

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.